ACME UNITED CORP - 10-Q Summary (Period Ended Sep 30, 1998)
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for ACME UNITED CORPORATION for the period ended September 30, 1998. The company manufactures and distributes consumer and medical products. Key operational developments during the period included the acquisition of the Rotex Division of Esselte Canada and the launch of the "Tagit!" children's scissor line. The company is currently negotiating with lenders to extend the maturity of its revolving line of credit, which is due in May 1999.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1998 | Nine Months Ended Sep 30, 1998 | Dec 31, 1997 (Balance Sheet) |
|---|---|---|---|
| Net Sales | $13,382,000 | $37,145,000 | N/A |
| Gross Profit Margin | 23.1% | 24.5% | N/A |
| Net Income | $70,000 | $97,000 | N/A |
| Diluted EPS | $0.02 | $0.03 | N/A |
| Cash and Equivalents | N/A | N/A | $331,000 (Sep 30, 1998) |
| Total Debt | N/A | N/A | $17,818,000 (Sep 30, 1998) |
| Working Capital | N/A | N/A | $1,648,000 (Sep 30, 1998) |
| Current Ratio | N/A | N/A | 1.07 to 1 (Sep 30, 1998) |
Note: Cash flow from operating activities for the nine months ended Sep 30, 1998, was a net use of $1,608,000.
Material Changes vs. Prior Period
- Revenue: Net sales increased 5% in the quarter and 2% for the nine-month period compared to 1997. Excluding the impact of the 1997 sale of Seton marketing rights, organic sales growth was 8% for both periods, driven largely by the Rotex acquisition.
- Profitability: Net income declined significantly to $70,000 for the quarter (down from $186,000 in 1997) and $97,000 for the nine months (down from $689,000 in 1997). The 1997 prior year included a one-time gain from the sale of marketing rights.
- Margins: Gross margins compressed across all segments. Consolidated gross margin fell from 26.7% to 23.1% in the quarter. Medical margins dropped from 37.3% to 26.8% due to the loss of high-margin Seton products and lower manufacturing efficiencies.
- Debt Structure: Total debt increased by $3,052,000 year-to-date. A significant portion of long-term debt ($14,542,000) is now classified as current due to the May 1999 maturity of the revolving line of credit.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects cash generated from operations to be sufficient to reduce debt and fund capital expenditures for the remainder of 1998. However, the current ratio of 1.07 is tight; management notes that if the credit extension is finalized, the current ratio would improve to 2.38.
- Debt Maturity: The company is in negotiations to extend the maturity of its $11.78 million revolving line of credit and fully expects to complete the arrangement before December 1998.
- Legal and Environmental: The company is involved in environmental matters and lawsuits regarding latex products. Management believes it is not reasonably possible that these will have a material adverse impact.
- Year 2000: Management believes the Year 2000 issue will not materially affect future financial results, citing a new information system implemented in 1997.
- Strategy: The company plans to consolidate sourcing from Asia to leverage buying power and improve margins. It also expects to expand the "Tagit!" product line.
Investor Verification Checklist
- Debt Extension: Verify the status of negotiations to extend the $11.78 million revolving credit facility maturing in May 1999.
- Liquidity Position: Monitor the current ratio and working capital, which are currently low ($1.65M working capital) due to the reclassification of debt.
- Margin Recovery: Assess whether the company can reverse the trend of declining gross margins in the medical and international segments.
- Seton Impact: Confirm that the decline in medical sales is not a permanent loss of market share but rather a one-time effect of the Seton divestiture.
- Operating Cash Flow: Review the continued negative operating cash flow ($1.6M used in 9 months) and its sustainability.